CIAM
CMPX icon

Caitong International Asset Management’s Compass Therapeutics CMPX Stock Holding History

Caitong International Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3K Buy
19,301
+18,582
+2,584% +$54.9K 0.01% 760
2026
Q1 		$3.8K Sell
719
-23,860
-97% -$138K ﹤0.01% 1162
2025
Q4 		$132K Buy
+24,579
New +$113K 0.03% 325

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caitong International Asset Management's CMPX Position: Q2 2026 in Review

Caitong International Asset Management increased its Compass Therapeutics (CMPX) stake by 2,584% in Q2 2026, buying an estimated $54.9K and bringing the position to 19,301 shares worth $42.3K. The position accounts for 0.01% of the portfolio, ranked #760.

Caitong International Asset Management first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $132K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Caitong International Asset Management held 19,301 shares of Compass Therapeutics worth $42.3K as of Q2 2026.
  • Caitong International Asset Management bought 18,582 Compass Therapeutics shares in Q2 2026, an estimated $54.9K.
  • Compass Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #760 holding.
  • Caitong International Asset Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's Compass Therapeutics position peaked at $132K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.